Access to UK Biobank data by researchers based in China has sparked headlines in the UK about potential security concerns, ...

Join the TPD & Induced Proximity Pharma Partnering Summit to accelerate partnership interest in your protein degradation ...

J&J said first-quarter revenues came in at $21.9 billion, up 2.4% on the same period of 2024, which was a little above ...

The EU approval comes after Eisai and Biogen were given approval for a new once-monthly intravenous maintenance dose of ...

Theravia made more than €50 million in revenues in 2024 and has seen its sales rise by an annual rate of around 10% in recent ...

Recorded onsite at The Eden Project in Cornwall, the conversation centred around the Adelphi Group-sponsored panel, ‘The ...

AI and digital health have tremendous potential to improve patient outcomes across healthcare, but in rare disease – where small patient groups, delayed diagnosis, and barriers to access create major ...

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared for phase 3 trials in asthma – even though it missed the mark in a midstage ...

By leveraging data, digitalisation, and artificial intelligence (AI), the network aims to transform its operations, making them more efficient and responsive to the challenges and opportunities of the ...

At Reuters Pharma USA last month, editor-in-chief Jonah Comstock caught up with John Androsavich, general manager of Ginkgo Datapoints, an AI-driven CRO launched by Ginkgo Bioworks last September. In ...

For decades, treatment options for rare diseases have been limited, often focusing on symptom management rather than ...

Shares in Ironwood Pharma fell by a third after it revealed that the FDA is insisting on a new phase 3 trial of its short ...